Shares of CombiMatrix Corporation (CBMX) soar today, finishing up over 334% after the New...

|About: CombiMatrix Corporation (CBMX)|By:, SA News Editor

Shares of CombiMatrix Corporation (CBMX) soar today, finishing up over 334% after the New England Journal of Medicine published two studies concluding chromonosomal microarray analysis (CMA) is superior to standard karyotyping for identifying prenatal genetic abnormalities. CBMX currently is the only publicly traded firm offering CMA diagnostics. One caveat, despite today's big run - the shares still are down over 55% from its $20 peak at the beginning of the year.